Achieving cancer cell death with PI3K/mTOR-targeted therapies

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

(2012) M. S. Davids et al.   BLOOD

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

(2012) C. Garcia-Garcia et al.   CLINICAL CANCER RESEARCH

Emerging Epigenetic Targets and Therapies in Cancer Medicine

(2012) Relja Popovic et al.   Cancer Discovery

PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

(2011) D. A. Fruman et al.   Cancer Discovery

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE